| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received May 21, 2002
Accepted after revision October 3, 2002
1 Department of Physiological Science, 5833 Life Science Building, University of California, Los Angeles, CA 90095, USA
2 Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
* To whom correspondence should be addressed. E-mail: jtidball{at}physci.ucla.edu.
Muscle wasting is a prominent feature of several systemic diseases, neurological damage and muscle disuse. The contribution of calpain proteases to muscle wasting in any instance of muscle injury or disease has remained unknown because of the inability to specifically perturb calpain activity in vivo. We have generated a transgenic mouse with muscle-specific overexpression of calpastatin, which is the endogenous inhibitor of calpains, and induced muscle atrophy by unloading hindlimb musculature for 10 days. Expression of the transgene resulted in increases in calpastatin concentration in muscle by 30- to 50-fold, and eliminated all calpain activity that was detectable on zymograms. Muscle fibres in ambulatory, transgenic mice were smaller in diameter, but more numerous, so that muscle mass did not differ between transgenic and non-transgenic mice. This is consistent with the role of the calpain-calpastatin system in muscle cell fusion that has been observed in vitro. Overexpression of calpastatin reduced muscle atrophy by 30 % during the 10 day unloading period. In addition, calpastatin overexpression completely prevented the shift in myofibrillar myosin content from slow to fast isoforms, which normally occurs in muscle unloading. These findings indicate that therapeutics directed toward regulating the calpain-calpastatin system may be beneficial in preventing muscle mass loss in muscle injury and disease.
This article has been cited by other articles:
|
|
 |
|
  I. J. Smith, S. H. Lecker, and P.-O. Hasselgren Calpain activity and muscle wasting in sepsis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E762 - E771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Goll, G. Neti, S. W. Mares, and V. F. Thompson Myofibrillar protein turnover: The proteasome and the calpains J Anim Sci, April 1, 2008; 86(14_suppl): E19 - E35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Chen, C. M. Gregory, M. T. Scarborough, R. Shi, G. A. Walter, and K. Vandenborne Transcriptional pathways associated with skeletal muscle disuse atrophy in humans Physiol Genomics, November 14, 2007; 31(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Powers, A. N. Kavazis, and J. M. McClung Oxidative stress and disuse muscle atrophy J Appl Physiol, June 1, 2007; 102(6): 2389 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vermaelen, P. Sirvent, F. Raynaud, C. Astier, J. Mercier, A. Lacampagne, and O. Cazorla Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1723 - C1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Smith and S. L. Dodd Muscle: Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle Exp Physiol, May 1, 2007; 92(3): 561 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Peter, G. Miller, and R. H. Crosbie Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice J. Cell Sci., March 15, 2007; 120(6): 996 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koncarevic, R. W. Jackman, and S. C. Kandarian The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension FASEB J, February 1, 2007; 21(2): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Judge, A. Koncarevic, R. B. Hunter, H.-C. Liou, R. W. Jackman, and S. C. Kandarian Role for I{kappa}B{alpha}, but not c-Rel, in skeletal muscle atrophy Am J Physiol Cell Physiol, January 1, 2007; 292(1): C372 - C382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Lecker, A. L. Goldberg, and W. E. Mitch Protein Degradation by the Ubiquitin-Proteasome Pathway in Normal and Disease States J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1807 - 1819. [Full Text] [PDF]
|
|
|
|
 |
|
 M. U. Fareed, A. R. Evenson, W. Wei, M. Menconi, V. Poylin, V. Petkova, B. Pignol, and P.-O. Hasselgren Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1589 - R1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Morris, L. D. Morris, A. R. Kennedy, and H. L. Sweeney Attenuation of skeletal muscle atrophy via protease inhibition J Appl Physiol, November 1, 2005; 99(5): 1719 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kramerova, E. Kudryashova, G. Venkatraman, and M. J. Spencer Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway Hum. Mol. Genet., August 1, 2005; 14(15): 2125 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klaus, B. Rudolph, C. Dohrmann, and R. Wehr Expression of uncoupling protein 1 in skeletal muscle decreases muscle energy efficiency and affects thermoregulation and substrate oxidation Physiol Genomics, April 14, 2005; 21(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wei, M. U. Fareed, A. Evenson, M. J. Menconi, H. Yang, V. Petkova, and P.-O. Hasselgren Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3 Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2005; 288(3): R580 - R590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Powers, A. N. Kavazis, and K. C. DeRuisseau Mechanisms of disuse muscle atrophy: role of oxidative stress Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R337 - R344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dapp, S. Schmutz, H. Hoppeler, and M. Fluck Transcriptional reprogramming and ultrastructure during atrophy and recovery of mouse soleus muscle Physiol Genomics, December 15, 2004; 20(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Jackman and S. C. Kandarian The molecular basis of skeletal muscle atrophy Am J Physiol Cell Physiol, October 1, 2004; 287(4): C834 - C843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Otani, D.-H. Han, E. L. Ford, P. M. Garcia-Roves, H. Ye, Y. Horikawa, G. I. Bell, J. O. Holloszy, and K. S. Polonsky Calpain System Regulates Muscle Mass and Glucose Transporter GLUT4 Turnover J. Biol. Chem., May 14, 2004; 279(20): 20915 - 20920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Kent, M. J. Spencer, and M. Koohmaraie Postmortem proteolysis is reduced in transgenic mice overexpressing calpastatin J Anim Sci, March 1, 2004; 82(3): 794 - 801. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
